RUA Life Sciences posts sharp increase in revenue

RUA Life Sciences reported a sharp increase in revenue for the 18 months ended 30 September on Tuesday, reflecting its successful transition from a research-led organisation to a revenue-generating medical device group.

  • RUA Life Sciences
  • 04 November 2025 16:15:57
RUA Life Sciences

Source: Sharecast

The AIM-traded company, which develops and commercialises implantable polymer technologies under the Elast-Eon brand, said revenue for the extended reporting period was expected to reach £6.6m, up from £2.2m in the 12 months to March 2024.

On a pro-rata basis, that equated to £4.4m, or £5.1m for the final 12 months of the period.

Growth was driven by the group’s shift from research and development to commercial operations.

Biomaterials royalties increased 80% to £0.9m, while the UK contract manufacturing division grew 105% to £3.5m.

The French subsidiary Abiss, acquired in September 2024, contributed £2.2m in revenue over its first full year of ownership.

RUA said it had also reduced its reliance on a single customer within its UK contract manufacturing business.

In the final six months of the period, its largest client accounted for 54% of revenue, down from about 95% previously, with 33% derived from a new supply contract announced in January and 13% from new business development.

The company said it expected to remain EBITDA positive for the full period, building on the £0.5m adjusted EBITDA profit reported for the 12 months to March, which included a £0.9m bargain purchase gain from the Abiss acquisition.

That compared with an EBITDA loss of £1.6m in the year to March 2024.

Cash utilisation fell significantly over the period, with the group expecting to report cash of £3.2m as at 30 September, down slightly from £3.5m in March due to higher working-capital needs linked to growth.

“The growth achieved by RUA over the past 18 months has been exceptional demonstrated both by the revenues reported and by the ever growing opportunities with existing and new customers,” said chief executive Bill Brown.

“This has been a true team effort and I am very grateful to everyone within the RUA Group for their contribution.”

RUA said it expected to publish its full audited results for the 18-month period by the end of January.

At 1556 GMT, shares in RUA Life Sciences were flat at 12p.

Reporting by Josh White for Sharecast.com.

N/A

Isin: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Bank of Scotland is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Bank of Scotland Share Dealing Service is operated by Halifax Share Dealing Limited. Halifax Share Dealing Limited. Registered in England and Wales No. 3195646. Registered Office: Trinity Road, Halifax, West Yorkshire HX1 2RG. Authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2025 Refinitiv, an LSEG business. All rights reserved.